Buccal (Mouth) Delivery
This oral delivery technology is built around a bioadhesive/mucoadhesive dextrin excipient beta-limit dextrin (BLD) which is manufactured by treating starch (amylopectin) with beta-amylase. The excipient is mixed with an active pharmaceutical ingredient (API) and freeze-dried to make 'wafers'. In the mouth, these lyophilised wafers deliver the API(s) through the mucosa into the blood stream. This is a rapidly growing area of drug delivery with many physiological advantages over other modes of delivery, e.g. misses first hepatic pass; speed of activity; ease of use; choke free risk of use (unlike tablets); suitable for infirm, infant and elderly users and; desirable sensory properties. The system also provides flexibility in terms of loading low and high therapeutic doses, flavours, colours, shapes etc. Different drugs (and active agents) can be delivered through the buccal mucosa using this technology. Trials have confirmed the efficacy of the technology (physical properties in the mouth and absorption through the mucosa of the mouth) in both animals (different species) and man.
Trials are under development for new drugs to be delivered in the buccal format.